RSK2 protects mice against TNF-induced bone loss

Journal of Cell Science

Volumn 125, Issue 9, 2012, Pages 2160-2171

  Böhm, Christina ^a   Derer, Anja ^a   Axmann, Roland ^a   Hillienhoff, Ulrike ^b   Zaiss, Mario M ^a   Luther, Julia ^a   Zech, Christine ^a   Stock, Michael ^a   Scholtysek, Carina ^a   Engelke, Klaus ^a   Hess, Andreas ^a   Tuckermann, Jan P ^b   Schett, Georg ^a   David, Jean Pierre ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

Apoptosis; Osteoblast; Osteocyte; Osteopenia; Rsk2; TNF; Tnf a

Indexed keywords

COLLAGEN TYPE 1; DENTIN MATRIX PROTEIN 1; OSTEOCALCIN; RSK2 PROTEIN; S6 KINASE; SCLEROSTIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DESTRUCTION; BONE GROWTH; BONE REMODELING; CELL COUNT; CONTROLLED STUDY; GROWTH RETARDATION; HUMAN; LONG BONE; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPENIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIBIA;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE RESORPTION; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCLASTS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

MUS; MUS MUSCULUS;

EID: 84862882990     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.096008     Document Type: Article

References (53)

1. Abu-Amer, Y., Erdmann, J., Alexopoulou, L., Kollias, G., Ross, F. P. and Teitelbaum, S. L. (2000). Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J. Biol. Chem. 275, 27307-27310.
2. Anjum, R. and Blenis, J. (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9, 747-758.
3. Anjum, R., Roux, P. P., Ballif, B. A., Gygi, S. P. and Blenis, J. (2005). The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr. Biol. 15, 1762-1767.
4. Böhm, C., Hayer, S., Kilian, A., Zaiss, M. M., Finger, S., Hess, A., Engelke, K., Kollias, G., Krönke, G., Zwerina, J. et al. (2009). The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J. Immunol. 183, 5938-5947.
5. Bonewald, L. F. (2011). The amazing osteocyte. J. Bone Miner. Res. 26, 229-238.
6. Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A. and Greenberg, M. E. (1999). Cell survival promoted by the Ras-MAPK signaling pathway by transcriptiondependent and -independent mechanisms. Science 286, 1358-1362.
7. Bruzzaniti, A. and Baron, R. (2006). Molecular regulation of osteoclast activity. Rev. Endocr. Metab. Disord. 7, 123-139.
8. Charatcharoenwitthaya, N., Khosla, S., Atkinson, E. J., McCready, L. K. and Riggs, B. L. (2007). Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J. Bone Miner. Res. 22, 724-729.
9. Cho, Y. Y., He, Z., Zhang, Y., Choi, H. S., Zhu, F., Choi, B. Y., Kang, B. S., Ma, W. Y., Bode, A. M. and Dong, Z. (2005). The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. Cancer Res. 65, 3596-3603.
10. David, J. P. and Schett, G. (2010). TNF and bone. Curr. Dir. Autoimmun. 11, 135-144.
11. David, J. P., Mehic, D., Bakiri, L., Schilling, A. F., Mandic, V., Priemel, M., Idarraga, M. H., Reschke, M. O., Hoffmann, O., Amling, M. et al. (2005). Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J. Clin. Invest. 115, 664-672.
12. Dehan, E., Bassermann, F., Guardavaccaro, D., Vasiliver-Shamis, G., Cohen, M., Lowes, K. N., Dustin, M., Huang, D. C., Taunton, J. and Pagano, M. (2009). betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol. Cell 33, 109-116.
13. Eisinger-Mathason, T. S., Andrade, J., Groehler, A. L., Clark, D. E., Muratore-Schroeder, T. L., Pasic, L., Smith, J. A., Shabanowitz, J., Hunt, D. F., Macara, I. G. et al. (2008). Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival. Mol. Cell 31, 722-736.
14. Gilbert, L., He, X., Farmer, P., Boden, S., Kozlowski, M., Rubin, J. and Nanes, M. S. (2000). Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 141, 3956-3964.
15. Gilbert, L., He, X., Farmer, P., Rubin, J., Drissi, H., van Wijnen, A. J., Lian, J. B., Stein, G. S. and Nanes, M. S. (2002). Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factoralpha. J. Biol. Chem. 277, 2695-2701.
16. Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L. and Khosla, S. (1999). Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25, 255-259.
17. Hogan, B., Beddington, R., Constantini, F. and Lacy, E. (1994). Manipulating The Mouse Embryo: A Laboratory Manual, 2nd edn. New York: Cold Spring Harbor Laboratory Press.
18. Jilka, R. L., Weinstein, R. S., Bellido, T., Parfitt, A. M. and Manolagas, S. C. (1998). Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 13, 793-802.
19. Jilka, R. L., Weinstein, R. S., Parfitt, A. M. and Manolagas, S. C. (2007). Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J. Bone Miner. Res. 22, 1492-1501.
20. Jochum, W., David, J. P., Elliott, C., Wutz, A., Plenk, H., Jr, Matsuo, K. and Wagner, E. F. (2000). Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6, 980-984.
21. Kang, S., Dong, S., Gu, T. L., Guo, A., Cohen, M. S., Lonial, S., Khoury, H. J., Fabbro, D., Gilliland, D. G., Bergsagel, P. L. et al. (2007). FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12, 201-214.
22. Karsenty, G., Kronenberg, H. M. and Settembre, C. (2009). Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 25, 629-648.
23. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D. and Kollias, G. (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031.
24. Kogianni, G., Mann, V. and Noble, B. S. (2008). Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J. Bone Miner. Res. 23, 915-927.
25. Lam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P. and Teitelbaum, S. L. (2000). TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488.
26. Li, Y., Li, A., Strait, K., Zhang, H., Nanes, M. S. and Weitzmann, M. N. (2007). Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J. Bone Miner. Res. 22, 646-655.
27. Lin, J. X., Spolski, R. and Leonard, W. J. (2008). Critical role for Rsk2 in Tlymphocyte activation. Blood 111, 525-533.
28. Lu, X., Gilbert, L., He, X., Rubin, J. and Nanes, M. S. (2006). Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways. J. Biol. Chem. 281, 6297-6306.
29. Marques Pereira, P., Schneider, A., Pannetier, S., Heron, D. and Hanauer, A. (2010). Coffin-Lowry syndrome. Eur. J. Hum. Genet. 18, 627-633.
30. Nakahama, K. (2010). Cellular communications in bone homeostasis and repair. Cell. Mol. Life Sci. 67, 4001-4009.
31. Nanes, M. S. (2003). Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321, 1-15.
32. Pacifici, R. (2008). Estrogen deficiency, T cells and bone loss. Cell. Immunol. 252, 68-80.
33. Peng, C., Cho, Y. Y., Zhu, F., Xu, Y. M., Wen, W., Ma, W. Y., Bode, A. M. and Dong, Z. (2010). RSK2 mediates NF-kappaB activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway. FASEB J. 24, 3490-3499.
34. Peng, C., Cho, Y. Y., Zhu, F., Zhang, J., Wen, W., Xu, Y., Yao, K., Ma, W. Y., Bode, A. M. and Dong, Z. (2011). Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J. Biol. Chem. 286, 6946-6954.
35. Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C. and Bellido, T. (1999). Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104, 1363-1374.
36. Poole, K. E., van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W. and Reeve, J. (2005). Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842-1844.
37. Raggatt, L. J. and Partridge, N. C. (2010). Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285, 25103-25108.
38. Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G. and Pacifici, R. (2001). Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98, 13960-13965.
39. Romeo, Y. and Roux, P. P. (2011). Paving the way for targeting RSK in cancer. Expert Opin. Ther. Targets 15, 5-9.
40. Schett, G. and David, J. P. (2010). The multiple faces of autoimmune-mediated bone loss. Nat. Rev. Endocrinol. 6, 698-706.
41. Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Görtz, B., Schulz, A., Bergmeister, H., Kollias, G. et al. (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum. 48, 2042-2051.
42. Schmidl, M., Adam, N., Surmann-Schmitt, C., Hattori, T., Stock, M., Dietz, U., de Crombrugghe, B., Pöüschl, E. and von der Mark, K. (2006). Twisted gastrulation modulates bone morphogenetic protein-induced collagen II and X expression in chondrocytes in vitro and in vivo. J. Biol. Chem. 281, 31790-31800.
43. Sfikakis, P. P. (2010). The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 11, 180-210.
44. Smith, J. A., Poteet-Smith, C. E., Xu, Y., Errington, T. M., Hecht, S. M. and Lannigan, D. A. (2005). Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 65, 1027-1034.
45. Tan, Y., Ruan, H., Demeter, M. R. and Comb, M. J. (1999). p90(RSK) blocks badmediated cell death via a protein kinase C-dependent pathway. J. Biol. Chem. 274, 34859-34867.
46. Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S. and Ikeda, K. (2007). Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5, 464-475.
47. Teitelbaum, S. L. and Ross, F. P. (2003). Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649.
48. Thomson, B. M., Mundy, G. R. and Chambers, T. J. (1987). Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J. Immunol. 138, 775-779.
49. Wachsmuth, L. and Engelke, K. (2004). High-resolution imaging of osteoarthritis using microcomputed tomography. Methods Mol. Med. 101, 231-248.
50. Wang, R., Jung, S. Y., Wu, C. F., Qin, J., Kobayashi, R., Gallick, G. E. and Kuang, J. (2010). Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc. Natl. Acad. Sci. USA 107, 19885-19890.
51. Yang, X., Matsuda, K., Bialek, P., Jacquot, S., Masuoka, H. C., Schinke, T., Li, L., Brancorsini, S., Sassone-Corsi, P., Townes, T. M. et al. (2004). ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117, 387-398.
52. Zaiss, M. M., Frey, B., Hess, A., Zwerina, J., Luther, J., Nimmerjahn, F., Engelke, K., Kollias, G., Hünig, T., Schett, G. et al. (2010). Regulatory T cells protect from local and systemic bone destruction in arthritis. J. Immunol. 184, 7238-7246.
53. Zhang, Y. H., Heulsmann, A., Tondravi, M. M., Mukherjee, A. and Abu-Amer, Y. (2001). Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276, 563-568.